	US 11,851,697 B2
	Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
Faycal Touti, Belmont, MA (US); Wendy Winckler Adamovich, Melrose, MA (US); Sophie Cazanave, Cambridge, MA (US); Mehar Cheema, Medford, MA (US); and Robert S. Langer, Newton, MA (US)
Assigned to Glympse Bio, Inc., Cambridge, MA (US)
Filed by Glympse Bio, Inc., Cambridge, MA (US)
Filed on Jan. 11, 2022, as Appl. No. 17/573,110.
Application 17/573,110 is a continuation in part of application No. PCT/US2021/049948, filed on Sep. 10, 2021.
Claims priority of provisional application 63/077,525, filed on Sep. 11, 2020.
Prior Publication US 2022/0128546 A1, Apr. 28, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); C12Q 1/37 (2006.01); G01N 21/64 (2006.01); G01N 33/58 (2006.01); G01N 33/573 (2006.01); G01N 33/542 (2006.01)

CPC C12Q 1/37 (2013.01) [G01N 21/6428 (2013.01); G01N 33/542 (2013.01); G01N 33/573 (2013.01); G01N 33/582 (2013.01); G01N 2021/6432 (2013.01); G01N 2021/6439 (2013.01); G01N 2021/6441 (2013.01); G01N 2333/95 (2013.01); G01N 2800/085 (2013.01); G01N 2800/26 (2013.01); G01N 2800/7028 (2013.01)]

18 Claims

1. A method comprising:

contacting a plasma sample from a subject with a synthetic molecule ex vivo,

wherein said synthetic molecule comprises a reporter and a cleavable linker, and

wherein said synthetic molecule reacts with an agent from said plasma sample,

wherein said agent cleaves said cleavable linker causing said reporter to form a detectable signal,

introducing an anticoagulant to said plasma sample,

detecting a rate of formation or an amount of said detectable signal,

determining a disease condition based on said rate of formation or amount of said released reporter;

wherein said disease condition comprises a liver disease.